Drug Profile
PL 8177
Alternative Names: PL-8177Latest Information Update: 18 Oct 2023
Price :
$50
*
At a glance
- Originator Palatin Technologies
- Class Anti-inflammatories; Cyclic peptides; Eye disorder therapies
- Mechanism of Action Melanocortin type 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Inflammatory bowel diseases; Ulcerative colitis
- Preclinical Arthritis; Diabetic nephropathies; Diabetic retinopathy
- No development reported COVID 2019 infections; Nephritis; Uveitis
Most Recent Events
- 16 Oct 2023 Pharmacodynamics data from a preclinical trial in Inflammatory bowel disease released by Palatin Technologies
- 28 Jul 2023 No recent reports of development identified for phase-I development in COVID-2019-infections in USA
- 30 May 2023 Preclinical trials in Diabetic nephropathies in USA (unspecified route) before May 2023